8-LavandulylkaempferolCAS# 883859-83-4 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 883859-83-4 | SDF | Download SDF |
| PubChem ID | 16083184 | Appearance | Yellow powder |
| Formula | C25H26O6 | M.Wt | 422.5 |
| Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-8-(5-methyl-2-prop-1-en-2-ylhex-4-enyl)chromen-4-one | ||
| SMILES | CC(=CCC(CC1=C(C=C(C2=C1OC(=C(C2=O)O)C3=CC=C(C=C3)O)O)O)C(=C)C)C | ||
| Standard InChIKey | RLJJIYPLHFCLRD-UHFFFAOYSA-N | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. 8-Lavandulylkaempferol exhibits significant inhibitory effects with IC(50) values of 7.10 and 8.11 microM for butyrylcholinesterase and acetylcholinesterase, respectively. 2. 8-Lavandulylkaempferol shows inhibitory activities against aldose reductase, with the the IC50 of 0.79 microM. |
| Targets | AChR |
8-Lavandulylkaempferol Dilution Calculator
8-Lavandulylkaempferol Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.3669 mL | 11.8343 mL | 23.6686 mL | 47.3373 mL | 59.1716 mL |
| 5 mM | 0.4734 mL | 2.3669 mL | 4.7337 mL | 9.4675 mL | 11.8343 mL |
| 10 mM | 0.2367 mL | 1.1834 mL | 2.3669 mL | 4.7337 mL | 5.9172 mL |
| 50 mM | 0.0473 mL | 0.2367 mL | 0.4734 mL | 0.9467 mL | 1.1834 mL |
| 100 mM | 0.0237 mL | 0.1183 mL | 0.2367 mL | 0.4734 mL | 0.5917 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Adrenorphin
Catalog No.:BCC1021
CAS No.:88377-68-8
- DPDPE
Catalog No.:BCC5758
CAS No.:88373-73-3
- (9Z,12Z)-N-(3-Methoxybenzyl)octadeca-9,12-dienamide
Catalog No.:BCN1316
CAS No.:883715-22-8
- N-Benzyloleamide
Catalog No.:BCN1317
CAS No.:101762-87-2
- N-Benzyllinolenamide
Catalog No.:BCN6531
CAS No.:883715-18-2
- E 64d
Catalog No.:BCC1127
CAS No.:88321-09-9
- BI 78D3
Catalog No.:BCC8089
CAS No.:883065-90-5
- CCG 50014
Catalog No.:BCC4897
CAS No.:883050-24-6
- HC 067047
Catalog No.:BCC7861
CAS No.:883031-03-6
- Polygalasaponin F
Catalog No.:BCN2317
CAS No.:882664-74-6
- AMG-47A
Catalog No.:BCC6394
CAS No.:882663-88-9
- Netobimin
Catalog No.:BCC9100
CAS No.:88255-01-0
- 8alpha-(2-Methylacryloyloxy)-1-O-methylhirsutinolide 13-O-acetate
Catalog No.:BCN7106
CAS No.:883872-71-7
- AZD2932
Catalog No.:BCC6388
CAS No.:883986-34-3
- Methyl syringate
Catalog No.:BCN4430
CAS No.:884-35-5
- L-(-)-α-Methyldopa hydrochloride
Catalog No.:BCC4083
CAS No.:884-39-9
- 6,7-Dihydroxycoumarin-4-Acetic Acid
Catalog No.:BCC9205
CAS No.:88404-14-2
- Buparvaquone
Catalog No.:BCC5437
CAS No.:88426-33-9
- (E)-FeCP-oxindole
Catalog No.:BCC6078
CAS No.:884338-18-5
- Murraxocin
Catalog No.:BCN4431
CAS No.:88478-44-8
- Artesunate
Catalog No.:BCN2457
CAS No.:88495-63-0
- Manassantin A
Catalog No.:BCC8207
CAS No.:88497-87-4
- Farrerol 7-O-glucoside
Catalog No.:BCN6412
CAS No.:885044-12-2
- Benzotetramisole
Catalog No.:BCC8861
CAS No.:885051-07-0
Selective inhibition of prenylated flavonoids from Sophora flavescens against BACE1 and cholinesterases.[Pubmed:20387235]
Am J Chin Med. 2010;38(2):415-29.
It was previously reported that certain lavandulylated flavanones from Sophora flavescens are beta-site APP cleaving enzyme 1 (BACE1) inhibitors; however, based upon their levels within the extract, their inhibitory effects should be higher than expected. Moreover, chalcones and flavonols were reported to exert higher bioactivities than flavanones. These findings have led to a further search for other possible constituents potentially contributing to the strong inhibitory activity of the S. flavescens extract. In this study, BACE1 activities were significantly inhibited by 8-Lavandulylkaempferol (IC(50) 7.29 microM), kuraridinol (IC(50) 7.10 microM), kuraridin (IC(50) 6.03 microM), and kushenol C (IC(50) 5.45 microM) from the ethyl acetate fraction, along with desmethylanhydroicaritin (IC(50) 1.86 microM), xanthohumol (IC(50) 7.19 microM), and leachianone G (IC(50) 8.56 microM) from the dichloromethane fraction of the extract. The results indicate that the prenyl group, rather than the lavandulyl group, and the flavonols and chalcones, rather than flavanones, might make predominant contributions to BACE1 inhibition. In particular, 8-Lavandulylkaempferol exhibited significant inhibitory effects with IC(50) values of 7.10 and 8.11 microM for butyrylcholinesterase and acetylcholinesterase, respectively, when compared to its counterpart, desmethylanhydroicaritin. This indicates that the lavandulyl group might play a predominant role in both cholinesterase inhibitions. This is the first study indicating that prenylated flavonoids exert varying degrees of inhibition primarily through their skeleton (flavonols, chalcones, flavanones), as well as their lipophilic chain length (prenyl and lavandulyl groups). Therefore, S. flavescens and its prenylated flavonoids, possessing low molecular weights and lipophilic moieties may be potent preventive and therapeutic candidates for Alzheimer's disease.
A new lavandulylated flavonoid with free radical and ONOO- scavenging activities from Sophora flavescens.[Pubmed:16392664]
Arch Pharm Res. 2005 Dec;28(12):1333-6.
A new lavandulylated flavonoid, 8-Lavandulylkaempferol (1), was isolated from the roots of Sophora flavescens AITON (Leguminosae). The structure of this compound was determined via spectroscopic analysis. Compound 1 was determined to be a scavenger on both 1,1-diphenyl-2-picrylhydrazyl radicals and ONOO-.
Inhibitory activities of prenylated flavonoids from Sophora flavescens against aldose reductase and generation of advanced glycation endproducts.[Pubmed:18718128]
J Pharm Pharmacol. 2008 Sep;60(9):1227-36.
Important targets for the prevention and treatment of diabetic complications include aldose reductase (AR) inhibitors (ARIs) and inhibitors of advanced glycation endproduct (AGE) formation. Here we evaluate the inhibitory activities of prenylated flavonoids isolated from Sophora flavescens, a traditional herbal medicine, on rat lens AR (RLAR), human recombinant AR (HRAR) and AGE formation. Among the tested compounds, two prenylated chalcones--desmethylanhydroicaritin (1) and 8-Lavandulylkaempferol (2)--along with five prenylated flavanones--kurarinol (8), kurarinone (9), (2S)-2'-methoxykurarinone (10), (2S)-3beta,7,4'-trihydroxy-5-methoxy-8-(gamma,gamma-dimethylally)-flavanone (11), and kushenol E (13) were potent inhibitors of RLAR, with IC50 values of 0.95, 3.80, 2.13, 2.99, 3.77, 3.63 and 7.74 microM, respectively, compared with quercetin (IC50 7.73 microM). In the HRAR assay, most of the prenylated flavonoids tested showed marked inhibitory activity compared with quercetin (IC50 2.54 microM). In particular, all tested prenylated flavonols, such as desmethylanhydroicaritin (1, IC50 0.45 microM), 8-Lavandulylkaempferol (2, IC50 0.79 microM) and kushenol C (3, IC50 0.85 microM), as well as a prenylated chalcone, kuraridin (5, IC50 0.27 microM), and a prenylated flavanone, (2S)-7,4'-dihydroxy-5-methoxy-8-(gamma,gamma-dimethylally)-flavanone (12, IC50 0.37 microM), showed significant inhibitory activities compared with the potent AR inhibitor epalrestat (IC50 0.28 microM). Interestingly, prenylated flavonoids 1 (IC50 104.3 microg mL(-1)), 2 (IC50 132.1 microg mL(-1)), 3 (IC50 84.6 microg mL(-1)) and 11 (IC50 261.0 microg mL(-1)), which harbour a 3-hydroxyl group, also possessed good inhibitory activity toward AGE formation compared with the positive control aminoguanidine (IC50 115.7 microg mL(-1)). Thus, S. flavescens and its prenylated flavonoids inhibit the processes that underlie diabetic complications and related diseases and may therefore have therapeutic benefit.
